Home›Trial›NCT05504837
NCT05504837Phase 1RECRUITING

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Study Summary

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Conditions
Cystic Fibrosis
Interventions / Drugs
KB407 (Nebulization)
View on ClinicalTrials.gov ↗
Sponsor
KRYS
Krystal Biotech
Gene Therapy
F29/100
Study Details
Enrollment12 participants
Primary Completion—
Lead SponsorKrystal Biotech, Inc.
Data Retrieved2026-04-11 04:19:09.549435+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 12 participants
Sponsor Catalyst Profile

Krystal Biotech (KRYS) is the sponsoring company for this trial. BiotechSign currently grades this company F (29/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

KRYS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.